Palvella Therapeutics (Nasdaq: PVLA) will report first quarter 2026 financial results before market open on Thursday, May 7, 2026. Management will host a conference call and webcast at 8:30 a.m. ET the same day to discuss results and provide a corporate update.
Investors can join the live webcast via the company’s Events & Presentations page or dial in at 800-715-9871 (domestic) or +1 646-307-1963 (international) using Conference ID 9970701. A replay will be archived for 90 days.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – PVLA
+4.80%
+4.80%Session close to close
In the Apr 30 session, PVLA gained 4.80%, reflecting a moderate positive market reaction.
This announcement sets the timing for Palvella’s Q1 2026 financial results and corporate update on M...
Analysis
This announcement sets the timing for Palvella’s Q1 2026 financial results and corporate update on May 7, 2026 at 8:30 a.m. ET. It follows a consistent pattern of quarterly and annual earnings calls with webcasts archived for 90 days. Investors can later compare the detailed Q1 metrics and pipeline commentary against prior updates, including recent Phase 3 data and financing disclosures, to evaluate how the company’s trajectory is evolving.
Planned full year 2024 financial results call and update on Mar 31, 2025.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Similar conference-call scheduling announcements have historically led to modest, mixed price moves, with an average reaction of about 0.53% in either direction.
Recent Company History
Recent same-tag history shows PVLA routinely pre-announcing earnings and update calls, such as Q1, Q2, Q3, and full-year results on Mar 31, 2025, May 15, 2025, Aug 14, 2025, Nov 11, 2025, and Mar 31, 2026. These events mainly served to set expectations for detailed financials and corporate updates, with generally modest share-price reactions and no consistent directional bias, framing today’s Q1 2026 call notice as part of an established communications cadence.
Key Terms
clinical-stage, biopharmaceutical, U.S. Food and Drug Administration (FDA), vascular malformations, +1 more
5 terms
clinical-stagemedical
"a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies"
Clinical-stage describes a drug, therapy, or company whose product is being tested in human trials but has not yet received regulatory approval. For investors, it signals that the project has moved beyond lab work into real-world testing—meaning higher potential reward if trials succeed but also clear risks from trial setbacks, costs, and regulatory delay; think of it like a prototype car on public road tests that could either prove its value or reveal problems that stop it from reaching production.
biopharmaceuticalmedical
"a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies"
A biopharmaceutical is a medicine made from living organisms or their components—such as proteins, cells or genetic material—rather than chemically synthesized compounds. For investors, these products can command high prices and long patent protection but also carry bigger development, manufacturing and regulatory risks; think of them like handcrafted, high-tech products that can generate strong returns if they work, but are costly and complex to produce.
U.S. Food and Drug Administration (FDA)regulatory
"for which there are no U.S. Food and Drug Administration (FDA)-approved therapies"
The U.S. Food and Drug Administration (FDA) is a government agency responsible for protecting public health by ensuring the safety and effectiveness of food, medicines, vaccines, and other health-related products. For investors, the FDA’s decisions can significantly impact companies in the healthcare and food industries, as approval or rejection of products can influence a company's success and stock performance.
vascular malformationsmedical
"rare skin diseases and vascular malformations for which there are no U.S. Food"
Abnormalities in the network of blood vessels present from birth that cause vessels to form oddly sized, shaped or connected channels rather than a normal, orderly pipeline; think of plumbing pipes that developed wrong connections and leak or bulge. They matter to investors because they create a defined patient group and clinical need that can drive demand for diagnostic tools, treatments, regulatory approvals and reimbursement decisions, affecting company revenues and risk profiles.
webcasttechnical
"To access the live webcast, including slides, please click here or visit"
A webcast is a live or recorded online event where people watch or listen to presentations, announcements, or performances through the internet. It’s like a TV broadcast but over the internet, allowing viewers from anywhere to tune in in real time or later. Webcasts are important because they let companies share information quickly and widely with audiences around the world.
WAYNE, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or “the Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced that it will report its first quarter 2026 financial results before market open on Thursday, May 7, 2026. Palvella management will host a conference call for investors at 8:30 a.m. ET on that same day to discuss the results and provide a corporate update.
To access the live webcast, including slides, please click here or visit the “Events & Presentations” section of Palvella’s website. To join the conference call by phone, dial 800-715-9871 (domestic) or +1 646-307-1963 (international) and provide Conference ID 9970701. Participants are encouraged to dial in approximately 15 minutes prior to the start of the call.
A replay of the webcast will be available approximately two hours after the call concludes and will be archived for 90 days in the “Events & Presentations” section of the Company’s website at www.palvellatx.com.
About Palvella Therapeutics Founded and led by rare disease biotech veterans, Palvella Therapeutics, Inc. (Nasdaq: PVLA) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Palvella is developing a broad pipeline of product candidates based on its patented QTORIN™ platform, with an initial focus on serious, rare skin diseases and vascular malformations, many of which are lifelong in nature. Palvella’s lead product candidate, QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin), is currently being developed for the treatment of microcystic lymphatic malformations, cutaneous venous malformations, and clinically significant angiokeratomas. Palvella’s second product candidate, QTORIN™ pitavastatin, is currently being developed for the treatment of disseminated superficial actinic porokeratosis. For more information, please visit www.palvellatx.com or follow Palvella on LinkedIn or X (formerly known as Twitter).
QTORIN™ rapamycin and QTORIN™ pitavastatin are for investigational use only and neither has been approved by the FDA or by any other regulatory agency for any indication.
When will Palvella Therapeutics (PVLA) release Q1 2026 results and hold the conference call?
Palvella will release Q1 2026 results before market open on Thursday, May 7, 2026. According to the company, management will host a conference call and webcast at 8:30 a.m. ET the same day to discuss the results and give a corporate update.
How can investors access the Palvella (PVLA) May 7, 2026 webcast and slides?
Investors can access the live webcast and slides on the company’s Events & Presentations web page. According to the company, the webcast includes slides and a replay will be available about two hours after the call and archived for 90 days.
What dial-in numbers and conference ID are for the Palvella (PVLA) May 7, 2026 call?
Dial 800-715-9871 (domestic) or +1 646-307-1963 (international) and use Conference ID 9970701. According to the company, participants are encouraged to dial in approximately 15 minutes before the 8:30 a.m. ET start time to ensure timely access.
Will a replay of the Palvella (PVLA) Q1 2026 call be available and for how long?
Yes, a replay will be available approximately two hours after the call concludes. According to the company, the replay will be archived on the Events & Presentations page and remain accessible for 90 days following the call.
